Harrow Health (HROW) Sees Unusually-High Trading Volume

Shares of Harrow Health (NASDAQ:HROW) saw unusually-high trading volume on Friday . Approximately 1,078,420 shares changed hands during mid-day trading, an increase of 333% from the previous session’s volume of 249,061 shares.The stock last traded at $6.11 and had previously closed at $5.86.

HROW has been the subject of a number of research reports. Zacks Investment Research downgraded Harrow Health from a “hold” rating to a “sell” rating in a research report on Wednesday, March 13th. TheStreet upgraded Harrow Health from a “d-” rating to a “c” rating in a research report on Wednesday, May 1st. Finally, ValuEngine downgraded Harrow Health from a “hold” rating to a “sell” rating in a research report on Wednesday, March 27th.

The company has a quick ratio of 3.22, a current ratio of 3.43 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $144.74 million, a P/E ratio of 10.08 and a beta of -0.02.

Harrow Health (NASDAQ:HROW) last announced its quarterly earnings data on Tuesday, March 12th. The company reported $0.77 EPS for the quarter, missing the Zacks’ consensus estimate of $0.84 by ($0.07). Harrow Health had a return on equity of 100.84% and a net margin of 65.84%. The firm had revenue of $11.38 million during the quarter, compared to the consensus estimate of $10.92 million. On average, equities analysts expect that Harrow Health will post -0.1 earnings per share for the current year.

In related news, Director Robert J. Kammer sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $6.91, for a total transaction of $69,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 30,000 shares of company stock valued at $162,500 in the last 90 days. 12.43% of the stock is owned by corporate insiders.

Several institutional investors have recently bought and sold shares of HROW. Birchview Capital LP bought a new position in shares of Harrow Health during the 1st quarter worth approximately $896,000. JPMorgan Chase & Co. bought a new position in shares of Harrow Health during the 1st quarter worth approximately $168,000. FineMark National Bank & Trust bought a new position in shares of Harrow Health during the 1st quarter worth approximately $113,000. Acadian Asset Management LLC bought a new position in shares of Harrow Health during the 1st quarter worth approximately $1,983,000. Finally, Alambic Investment Management L.P. bought a new position in shares of Harrow Health during the 1st quarter worth approximately $252,000. Institutional investors and hedge funds own 24.18% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Harrow Health (HROW) Sees Unusually-High Trading Volume” was first published by Stock Observer and is owned by of Stock Observer. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.thestockobserver.com/2019/05/17/harrow-health-hrow-sees-unusually-high-trading-volume.html.

About Harrow Health (NASDAQ:HROW)

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Featured Article: Recession

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.